ATXN5 - Ataxin-5

ATXN5 - Ataxin-5

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background-color: #4a90d9; color: white; text-align: center;">ATXN5</th></tr>
<tr><td colspan="2" style="text-align: center; padding: 10px;"><b>Ataxin-5</b></td></tr>
<tr><th style="width: 40%;">Symbol</th><td>ATXN5</td></tr>
<tr><th>Full Name</th><td>Ataxin-5</td></tr>
<tr><th>Chromosome</th><td>14q32.1</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/58516" target="_blank">58516</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/600753" target="_blank">600753</a></td></tr>
<tr><th>Ensembl ID</th><td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145833" target="_blank">ENSG00000145833</a></td></tr>
<tr><th>UniProt</th><td><a href="https://www.uniprot.org/uniprot/Q9UH92" target="_blank">Q9UH92</a></td></tr>
<tr><th>Protein Length</th><td>828 amino acids</td></tr>
<tr><th>Associated Diseases</th><td>Spinocerebellar Ataxia Type 5 (SCA5)</td></tr>
</table>
</div>

Overview

ATXN5 - Ataxin-5

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background-color: #4a90d9; color: white; text-align: center;">ATXN5</th></tr>
<tr><td colspan="2" style="text-align: center; padding: 10px;"><b>Ataxin-5</b></td></tr>
<tr><th style="width: 40%;">Symbol</th><td>ATXN5</td></tr>
<tr><th>Full Name</th><td>Ataxin-5</td></tr>
<tr><th>Chromosome</th><td>14q32.1</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/58516" target="_blank">58516</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/600753" target="_blank">600753</a></td></tr>
<tr><th>Ensembl ID</th><td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145833" target="_blank">ENSG00000145833</a></td></tr>
<tr><th>UniProt</th><td><a href="https://www.uniprot.org/uniprot/Q9UH92" target="_blank">Q9UH92</a></td></tr>
<tr><th>Protein Length</th><td>828 amino acids</td></tr>
<tr><th>Associated Diseases</th><td>Spinocerebellar Ataxia Type 5 (SCA5)</td></tr>
</table>
</div>

Overview

ATXN5 (Ataxin-5) encodes a protein of 828 amino acids that is the pathogenic driver of Spinocerebellar Ataxia type 5 (SCA5), an autosomal dominant neurodegenerative disorder characterized by pure cerebellar ataxia. SCA5 was historically known as "the plain's ataxia" due to its prevalence in a large American family descending from a 19th-century Kansas pioneer [@flanigan1996]. The disease manifests as a progressive cerebellar syndrome, with patients typically presenting in the third to fourth decade of life with gait instability, limb ataxia, and dysarthria. Unlike many other polyglutamine (polyQ) diseases, SCA5 is caused by polyQ expansions that lead to toxic gain-of-function rather than the typical nuclear aggregation seen in other SCAs. Ataxin-5 is a nuclear-cytoplasmic protein involved in transcriptional regulation, protein quality control, and synaptic function [@abraham2019]. Recent research has revealed that SCA5 exhibits unusual pathological features compared to other polyQ diseases, including a relative absence of prominent nuclear inclusions and instead displays a diffuse cytoplasmic distribution of the mutant protein [@bower2020]. This distinctive pattern suggests that the pathogenic mechanisms in SCA5 may differ substantially from other SCAs, potentially involving disruptions in cytoplasmic signaling pathways, synaptic function, and mitochondrial homeostasis rather than classical nuclear aggregation-mediated toxicity.

Gene Structure and Protein Architecture

The ATXN5 gene spans approximately 30 kb on chromosome 14q32.1 and encodes a protein with several distinct domains:

Protein Structure

Normal Biological Functions

Ataxin-5 participates in several essential cellular processes:

Transcriptional Regulation

• Nuclear receptor coactivator: Interacts with nuclear receptors and coactivators
• Gene expression control: Regulates neuronal gene expression programs
• Chromatin remodeling: May influence chromatin structure

Protein Quality Control

• Proteasome interactions: Associates with the ubiquitin-proteasome system
• Autophagy regulation: Contributes to cellular clearance pathways
• Protein homeostasis: Maintains neuronal protein equilibrium

Synaptic Function

• Synaptic protein complexes: Part of synaptic protein networks
• Neuronal transmission: Affects neurotransmitter release
• Synaptic plasticity: Involved in activity-dependent plasticity
• Presynaptic function: Ataxin-5 localizes to presynaptic terminals where it regulates vesicle trafficking and neurotransmitter release machinery
• Postsynaptic signaling: Interacts with postsynaptic density proteins to modulate synaptic signaling cascades
• Synapse assembly: Contributes to formation and maintenance of excitatory synapses, particularly in cerebellar neurons

Cellular Stress Response

Ataxin-5 plays a critical role in the cellular stress response network:

• Oxidative stress: Protects neurons against oxidative damage through activation of antioxidant response pathways
• ER stress: Modulates the unfolded protein response (UPR) to maintain ER homeostasis
• Heat shock response: Associates with heat shock proteins to facilitate proper protein folding under cellular stress
• DNA damage response: Participates in neuronal DNA damage repair mechanisms

Expression Patterns

Central Nervous System

ATXN5 is expressed in various brain regions:

• Cerebellum: Highest expression in Purkinje cells
• Cerebral cortex: Pyramidal neurons
• Hippocampus: All regions
• Brainstem: Motor and sensory nuclei
• Spinal cord: Motor neurons

Cellular Localization

• Nucleus: Primary location in neurons
• Cytoplasm: Subset of protein in cytoplasmic compartment
• Synapses: Present at synaptic terminals

Disease Associations

Spinocerebellar Ataxia Type 5 (SCA5)

Epidemiology: SCA5 accounts for approximately 5-10% of autosomal dominant cerebellar ataxias. The prevalence varies geographically, with certain populations showing higher frequencies due to founder mutations. The original "Lincoln" kindred described by Flanigan et al. represents the largest documented SCA5 family, with over 400 affected individuals spanning seven generations [@flanigan1996].

Genetics:

• Inheritance: Autosomal dominant
• Mutation: CAG repeat expansion (polyQ expansion)
• Normal repeat: 19-35 glutamines
• Disease repeat: 47-69 glutamines
• Penetrance: Full penetrance by middle age
• Anticipation: Observed in some families, with earlier onset in subsequent generations typically associated with paternal transmission

• Onset: Typically 20-40 years (range 10-60 years)
• Core symptoms:
• Progressive gait ataxia
• Limb dysmetria and incoordination
• Dysarthria (scanning speech)
• Nystagmus (horizontal, gaze-evoked)
• Hyperreflexia (early)
• Disease course: Slowly progressive over decades
• Cognitive function: Generally preserved
• Saccadic intrusions: Horizontal saccadic intrusions without pause (SICPAR) represent a characteristic oculomotor finding
• Eye movement abnormalities: Impaired smooth pursuit and gaze-holding deficits
• Motor function: Hyperreflexia in early stages, potentially transitioning to hyporeflexia in later stages

Molecular Mechanisms

Pathogenic Mechanisms

• Toxic gain-of-function: Mutant protein acquires novel toxic functions
• Transcriptional disruption: Impairs normal transcriptional regulatory functions
• Protein network disruption: Interferes with normal protein interactions
• Synaptic impairment: Affects cerebellar synaptic function

Protein-Protein Interactions

Ataxin-5 participates in a complex network of protein interactions:

• Nuclear receptor coactivators: Interacts with PPARGC1A (PGC-1α), NCoA1, and NCoA2 to regulate mitochondrial biogenesis and energy metabolism
• Transcription factors: Binds to CREB, ATF4, and FOXO transcription factors to modulate stress response gene expression
• Chaperone proteins: Associates with Hsp70, Hsp90, and Bag1 for protein quality control
• Proteasome components: Interacts with 19S regulatory particle subunits for ubiquitin-dependent protein degradation
• Synaptic proteins: Partners with PSD-95, Synapsin, and Bassoon at synaptic terminals

Cellular Pathways Affected

• Nuclear receptor signaling: Disrupted coactivator function
• Protein homeostasis: Impaired quality control
• Synaptic transmission: Altered neurotransmitter release
• Cytoskeletal function: Affected neuronal morphology
• Mitochondrial function: Altered energy metabolism and ROS handling
• Autophagy-lysosomal pathway: Impaired cellular clearance mechanisms

Protein-Protein Interactions

Ataxin-5 participates in several critical protein interaction networks:

Nuclear Receptor Complexes

Ataxin-5 interacts with nuclear receptors through its LxxLL motif:

• PPARγ: Modulates lipid metabolism and mitochondrial function
• GR: Influences neuronal stress responses
• TRs: Essential for cerebellar development and maintenance

Transcriptional Co-regulators

• CBP/p300: Histone acetyltransferase complexes
• PGC-1α: Master regulator of mitochondrial biogenesis
• NCoR/SMRT: Nuclear receptor co-repressor complexes

Protein Quality Control Components

• Proteasome subunits: 26S proteasome for targeted degradation
• HSP70/HSP90: Molecular chaperones
• Autophagy receptors: p62/SQSTM1 and LC3

Protein-Protein Interactions

Ataxin-5 participates in several critical protein interaction networks:

Nuclear Receptor Complexes

Ataxin-5 interacts with nuclear receptors through its LxxLL motif:

• PPARγ: Modulates lipid metabolism and mitochondrial function
• GR: Influences neuronal stress responses
• TRs: Essential for cerebellar development and maintenance

Transcriptional Co-regulators

• CBP/p300: Histone acetyltransferase complexes
• PGC-1α: Master regulator of mitochondrial biogenesis
• NCoR/SMRT: Nuclear receptor co-repressor complexes

Protein Quality Control Components

• Proteasome subunits: 26S proteasome for targeted degradation
• HSP70/HSP90: Molecular chaperones
• Autophagy receptors: p62/SQSTM1 and LC3

Therapeutic Approaches

Current Strategies

• Symptomatic treatment: Physical therapy, occupational therapy
• Speech therapy: For dysarthria
• Assistive devices: Walking aids as disease progresses

Future Directions

• Gene therapy: Delivering wild-type ATXN5
• RNA targeting: siRNA/ASO approaches
• Aggregation inhibitors: Blocking toxic protein aggregation
• Neuroprotective strategies: Enhancing neuronal survival

Drug Development Pipeline

Several therapeutic approaches are under investigation:

| Approach | Target | Stage | Notes |
|----------|--------|-------|-------|
| ASO therapy | Mutant ATXN5 mRNA | Preclinical | Reduce toxic protein |
| AAV-vectored gene therapy | Wild-type ATXN5 | Research | Restore normal function |
| Aggregation inhibitors | Protein aggregates | Discovery | Prevent toxicity |
| Neuroprotective agents | Multiple pathways | Preclinical | Enhance survival |

Clinical Trials

While no SCA5-specific clinical trials are currently active, the field is advancing:

• Natural history studies: Understanding disease progression
• Biomarker studies: Developing outcome measures
• International registries: Patient recruitment infrastructure

Genetic Counseling and Family Planning

SCA5 exhibits autosomal dominant inheritance with complete penetrance. Genetic testing is available for at-risk family members. Preimplantation genetic diagnosis (PGD) can be used for families wishing to avoid passing the mutation to offspring.

Testing Recommendations

• At-risk individuals: Age 18+ or before reproduction
• Prenatal testing: Available for pregnancies
• Carrier testing: Important for family planning

Genotype-Phenotype Correlations

The relationship between ATXN5 genotype and SCA5 phenotype has been characterized:

• Repeat length: Disease severity correlates with polyQ expansion length
• Age of onset: Longer repeats generally correlate with earlier onset (typically 20-40 years)
• Disease progression: Rate of progression shows individual variation
• Anticipation: Parent-to-child transmission shows earlier onset in subsequent generations

Phenotypic Spectrum

SCA5 exhibits a relatively narrow phenotypic spectrum compared to other SCAs:

• Classic form: Progressive cerebellar ataxia with intact cognitive function
• Mild form: Later onset with slower progression
• Severe form: Early onset with rapid progression (rare)

Comparison with Other Spinocerebellar Ataxias

SCA5 is notable for causing relatively "pure" cerebellar ataxia:

| SCA Type | Gene | Phenotype |
|----------|------|-----------|
| SCA1 | ATXN1 | Ataxia + oculomotor palsy |
| SCA2 | ATXN2 | Ataxia + slow saccades |
| SCA5 | ATXN5 | Pure cerebellar ataxia |
| SCA6 | CACNA1A | Pure cerebellar ataxia |

Unlike some other SCAs, SCA5 typically presents with pure cerebellar features without significant extraneurological manifestations.

Prognosis and Quality of Life

SCA5 has a relatively favorable prognosis compared to other neurodegenerative ataxias:

• Life expectancy: Normal or near-normal
• Disease progression: Slow, often decades
• Disability: Variable, many remain ambulatory
• Cognitive function: Preserved throughout disease course

Functional Outcomes

• Ambulation: Most remain ambulatory 10+ years
• Daily activities: Adaptive equipment helps independence
• Communication: Speech therapy beneficial
• Employment: Depends on occupation and progression

Biomarker Development

Disease Progression Biomarkers

• Motor assessments: Quantitative ataxia rating scales
• Imaging markers: Cerebellar volume changes on MRI
• Biochemical markers: Protein levels in cerebrospinal fluid

Therapeutic Response Biomarkers

• Target engagement: ATXN5 expression levels
• Pharmacodynamic markers: Downstream pathway activation
• Clinical endpoints: Functional improvement measures

Evolutionary Conservation

| Species | Gene | Amino Acids | Identity |
|---------|------|-------------|----------|
| Human | ATXN5 | 828 | Reference |
| Mouse | Atxn5 | 819 | 87% |
| Zebrafish | atxn5 | 756 | 65% |

Clinical Management

Diagnostic Approach

Management Strategies

| Approach | Description | Efficacy |
|----------|-------------|----------|
| Physical therapy | Balance and gait training | High |
| Occupational therapy | ADL optimization | Moderate |
| Speech therapy | Dysarthria management | Moderate |
| Pharmacotherapy | Symptomatic relief | Limited |

Biochemical and Molecular Mechanisms

Protein Structure and Function

Ataxin-5 contains several functional domains:

N-terminal Region:

• Polyglutamine tract (normal vs expanded)
• Protein-protein interaction motifs

• Mediates protein interactions
• Scaffold for signaling complexes

Aggregation Mechanisms

The polyQ expansion leads to toxic aggregation:

• Conformational change: Altered protein folding
• Oligomer formation: Early toxic species
• Aggregate accumulation: Cellular dysfunction

Future Therapeutic Directions

Gene Replacement Therapy

• AAV-mediated delivery of wild-type ATXN5
• Promoter selection for appropriate expression levels
• Targeting cerebellar Purkinje cells specifically

RNA-Based Therapies

• Antisense oligonucleotides (ASOs) to reduce mutant ATXN5 expression
• RNA interference (RNAi) approaches
• Small molecule modifiers of RNA splicing

Small Molecule Approaches

• Proteostasis modulators to enhance protein clearance
• Neuroprotective compounds
• Mitochondrial function enhancers

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia)
• [Polyglutamine Diseases](/mechanisms/polyglutamine-diseases)
• [Cerebellum](/brain-regions/cerebellum)
• [Purkinje Cells](/cell-types/purkinje-cells)

External Links

• [NCBI Gene: ATXN5](https://www.ncbi.nlm.nih.gov/gene/58516)
• [Ensembl: ENSG00000145833](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145833)
• [UniProt: Q9UH92](https://www.uniprot.org/uniprot/Q9UH92)
• [OMIM: 600753](https://www.omim.org/entry/600753)

References